And again, these data confirm that VEGFB treatment via NRP1 also effectively attenuated hypoxia-induced ferroptosis pathways in the cardiomyocytes, demonstrating that VEGFB/NRP1 signaling presents an additional therapeutic avenue as ferroptosis is increasingly recognized as a key contributor to cardiomyocyte loss in HF. This evidence concerns the gene VEGFB and hydrops fetalis.